Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SAL056 in postmenopausal women with osteoporosis at high fracture risk
CTR20261615Phase 2Active
- Sponsor
- Chengdu Jinkai Biotechnology
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Xinfutai in postmenopausal osteoporosis, sponsored by Chengdu Jinkai Biotechnology. Started Apr 2026; status: active.
02
Drugs
Xinfutai
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20261615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261615.